Subtopic Deep Dive
Primary Cutaneous CD30+ Lymphoproliferative Disorders
Research Guide
What is Primary Cutaneous CD30+ Lymphoproliferative Disorders?
Primary Cutaneous CD30+ Lymphoproliferative Disorders encompass lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma, characterized by CD30-positive T-cell proliferations confined to the skin without extracutaneous involvement.
These disorders represent the second most common cutaneous T-cell lymphomas, with lymphomatoid papulosis showing self-regressing papules and anaplastic large-cell lymphoma presenting as nodules or tumors. The WHO-EORTC classification systems define their diagnostic criteria based on clinicopathologic features (Willemze et al., 2005, 3766 citations; Willemze et al., 2019, 1301 citations). Long-term follow-up of 219 patients confirmed excellent prognosis with conservative management (Bekkenk et al., 2000, 776 citations).
Why It Matters
Distinguishing lymphomatoid papulosis from primary cutaneous anaplastic large-cell lymphoma determines conservative therapy versus radiotherapy or brentuximab vedotin, avoiding overtreatment in indolent cases. Bekkenk et al. (2000) reported 5-year survival rates exceeding 90% with skin-directed approaches for 118 lymphomatoid papulosis patients. Willemze et al. (2011) provided EORTC consensus guidelines emphasizing biopsy confirmation to guide therapy (413 citations). Brentuximab vedotin showed efficacy in CD30+ cutaneous T-cell lymphomas, including relapsed cases (Prince et al., 2017, 567 citations).
Key Research Challenges
Differential Diagnosis Overlap
Clinicopathologic features of lymphomatoid papulosis overlap with primary cutaneous anaplastic large-cell lymphoma and secondary CD30+ infiltrates, complicating classification. Willemze et al. (2005) highlighted shortcomings in prior WHO-EORTC systems leading to misdiagnosis in 10-20% of cases. Long-term follow-up data from 219 patients underscore need for serial biopsies (Bekkenk et al., 2000).
ALK Expression Variability
Distinguishing ALK-negative primary cutaneous cases from systemic anaplastic large-cell lymphoma requires immunophenotyping and genetic profiling. Savage et al. (2008) reported ALK- ALCL differs clinically from ALK+ and PTCL-NOS in 22-institution cohort (845 citations). Stein et al. (2000) detailed histopathologic features but noted diagnostic pitfalls (935 citations).
Optimal Therapy Selection
Balancing conservative management against systemic agents like brentuximab vedotin remains unresolved for multifocal disease. Kempf et al. (2011) consensus recommends skin-directed therapy first but lacks randomized data (413 citations). Prince et al. (2017) phase 3 trial showed brentuximab superiority in CD30+ CTCL but excluded indolent cases.
Essential Papers
WHO-EORTC classification for cutaneous lymphomas
Rein Willemze · 2005 · Blood · 3.8K citations
Primary cutaneous lymphomas are currently classified by the European Organization for Research and Treatment of Cancer (EORTC) classification or the World Health Organization (WHO) classification, ...
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Rein Willemze, Lorenzo Cerroni, Werner Kempf et al. · 2019 · Blood · 1.3K citations
Abstract Primary cutaneous lymphomas are a heterogeneous group of T- and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. The 2005 Worl...
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · 2012 · Journal of Clinical Oncology · 976 citations
Purpose Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T-cell lymphoma characterized by the uniform expression of CD30. The antibody-drug conjugate brentuximab vedotin d...
CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
Harald Stein, Hans‐Dieter Foss, Horst Dürkop et al. · 2000 · Blood · 935 citations
Abstract Anaplastic large cell lymphoma (ALCL) represents a generally recognized group of large cell lymphomas. Defining features consist of a proliferation of predominantly large lymphoid cells wi...
ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
Kerry J. Savage, Nancy L. Harris, Julie M. Vose et al. · 2008 · Blood · 845 citations
Abstract The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer (NK)/T-cell lymphomas (PTCLs). ...
Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment
Marcel W. Bekkenk, Françoise A. M. J. Geelen, Pieter C. van Voorst Vader et al. · 2000 · Blood · 776 citations
Abstract To evaluate our diagnostic and therapeutic guidelines, clinical and long-term follow-up data of 219 patients with primary or secondary cutaneous CD30+ lymphoproliferative disorders were ev...
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince, Youn H. Kim, Sarah McCue Horwitz et al. · 2017 · The Lancet · 567 citations
Reading Guide
Foundational Papers
Start with Willemze et al. (2005, Blood, 3766 citations) for WHO-EORTC classification establishing diagnostic criteria; then Bekkenk et al. (2000, 776 citations) for 219-patient outcomes validating conservative management.
Recent Advances
Willemze et al. (2019, 1301 citations) classification update refining subtypes; Prince et al. (2017, 567 citations) ALCANZA trial establishing brentuximab vedotin efficacy.
Core Methods
CD30/ALK immunohistochemistry, T-cell receptor gene rearrangement PCR, long-term clinicopathologic follow-up; EORTC consensus skin-directed therapies (Kempf et al., 2011).
How PapersFlow Helps You Research Primary Cutaneous CD30+ Lymphoproliferative Disorders
Discover & Search
Research Agent uses citationGraph on Willemze et al. (2005, 3766 citations) to map 50+ related papers on WHO-EORTC classifications, then findSimilarPapers identifies Bekkenk et al. (2000) long-term follow-up studies. exaSearch queries 'primary cutaneous CD30+ lymphoproliferative disorders long-term outcomes' surfaces Dutch Cutaneous Lymphoma Group data.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival rates from Bekkenk et al. (2000), then verifyResponse with CoVe cross-checks against Willemze et al. (2019) updates. runPythonAnalysis processes citation networks with pandas to verify 90%+ survival claims; GRADE grading scores evidence as high for observational cohorts.
Synthesize & Write
Synthesis Agent detects gaps in randomized trials for therapy selection via contradiction flagging between Kempf consensus (2011) and brentuximab trials (Prince 2017). Writing Agent uses latexEditText for case reports, latexSyncCitations integrates 10 key papers, and latexCompile generates formatted reviews; exportMermaid visualizes diagnostic flowcharts.
Use Cases
"Extract survival statistics from CD30+ cutaneous lymphoma cohorts and plot Kaplan-Meier curves"
Research Agent → searchPapers 'Bekkenk 2000 CD30+' → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib for survival curves) → researcher gets CSV data and GRADE-verified plots.
"Write LaTeX review of WHO-EORTC classifications for primary cutaneous CD30+ disorders"
Synthesis Agent → gap detection on Willemze 2005/2019 → Writing Agent → latexEditText + latexSyncCitations (10 papers) + latexCompile → researcher gets compiled PDF with diagrams.
"Find code repositories analyzing CD30 expression in cutaneous lymphoma datasets"
Research Agent → citationGraph on Stein 2000 → Code Discovery → paperExtractUrls + paperFindGithubRepo + githubRepoInspect → researcher gets inspected R scripts for IHC quantification.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CD30+ papers: searchPapers → citationGraph → readPaperContent → GRADE grading → structured report on outcomes. DeepScan applies 7-step verification to Bekkenk et al. (2000) data: exaSearch → CoVe → runPythonAnalysis for stats. Theorizer generates hypotheses on ALK- vs ALK+ progression from Savage et al. (2008) cohort.
Frequently Asked Questions
What defines Primary Cutaneous CD30+ Lymphoproliferative Disorders?
Spectrum including lymphomatoid papulosis (self-healing papules) and primary cutaneous anaplastic large-cell lymphoma (nodules/tumors), both CD30+ without extracutaneous disease at diagnosis (Willemze et al., 2005).
What are key diagnostic methods?
Skin biopsy with CD30 immunohistochemistry, ALK negativity confirms cutaneous origin; clinicopathologic correlation essential (Stein et al., 2000; Kempf et al., 2011).
What are seminal papers?
Willemze et al. (2005, 3766 citations) WHO-EORTC classification; Bekkenk et al. (2000, 776 citations) 219-patient follow-up; Willemze et al. (2019, 1301 citations) update.
What open problems persist?
Lack of randomized trials for multifocal disease therapy; molecular predictors of progression from indolent to aggressive forms (Savage et al., 2008; Prince et al., 2017).
Research Cutaneous lymphoproliferative disorders research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Primary Cutaneous CD30+ Lymphoproliferative Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers